[{"address1": "Avinguda de la Generalitat, 152", "address2": "Parc empresarial Can Sant Joan Sant Cugat del Valles", "city": "Barcelona", "zip": "08174", "country": "Spain", "phone": "34 935 712 200", "fax": "34 938 008 000", "website": "https://www.grifols.com", "industry": "Drug Manufacturers\u2014General", "sector": "Healthcare", "longBusinessSummary": "Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.", "fullTimeEmployees": 23505, "companyOfficers": [{"maxAge": 1, "name": "Mr. Thomas H. Glanzmann", "age": 65, "title": "Executive Chairman", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 2123649, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jose Ignacio  Abia Buenache", "age": 55, "title": "CEO & Director", "yearBorn": 1968, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alfredo Arroyo Guerra", "age": 65, "title": "CFO & VP", "yearBorn": 1958, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Lluis Pons Gomez", "age": 40, "title": "Senior Vice President of Strategy & COO Office", "yearBorn": 1983, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Nuria Pascual Lape\u00f1a", "age": 59, "title": "VP of Corporate Treasury, Risk Management Investor Relation & Sustainability Officer", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David Ian Bell", "age": 69, "title": "Chief Corporate Development, Legal & Data Protection Officer", "yearBorn": 1954, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Maria  Teresa-Rion\u00e9 Llano", "age": 58, "title": "Chief Communications Officer", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Camille  Alpi", "age": 42, "title": "Chief Human Resources & Talent Officer", "yearBorn": 1981, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Vicente  Blanquer Torre", "age": 62, "title": "Chief Quality Officer", "yearBorn": 1961, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Sergio Roura Adell", "age": 55, "title": "President of Commercial Tech Support", "yearBorn": 1968, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 2, "boardRisk": 4, "compensationRisk": 4, "shareHolderRightsRisk": 8, "overallRisk": 3, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 9.65, "open": 9.65, "dayLow": 9.65, "dayHigh": 9.65, "regularMarketPreviousClose": 9.65, "regularMarketOpen": 9.65, "regularMarketDayLow": 9.65, "regularMarketDayHigh": 9.65, "exDividendDate": 1622678400, "fiveYearAvgDividendYield": 1.42, "beta": 0.722, "trailingPE": 32.037033, "volume": 110, "regularMarketVolume": 110, "averageVolume": 387, "averageVolume10days": 10, "averageDailyVolume10Day": 10, "bid": 10.52, "ask": 10.85, "bidSize": 43500, "askSize": 41800, "marketCap": 7024457216, "fiftyTwoWeekLow": 7.46, "fiftyTwoWeekHigh": 15.8, "priceToSalesTrailing12Months": 1.031394, "fiftyDayAverage": 9.4278, "twoHundredDayAverage": 10.31135, "currency": "USD", "enterpriseValue": 17826686976, "profitMargins": 0.024330001, "floatShares": 546972376, "sharesOutstanding": 422184992, "heldPercentInsiders": 0.31382, "heldPercentInstitutions": 0.35114, "bookValue": 8.229, "priceToBook": 1.0511605, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "earningsQuarterlyGrowth": -0.611, "netIncomeToCommon": 165672992, "trailingEps": 0.27, "lastSplitFactor": "2:1", "lastSplitDate": 1451865600, "enterpriseToRevenue": 2.617, "enterpriseToEbitda": 16.039, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "GIFLF", "underlyingSymbol": "GIFLF", "shortName": "Grifols Sa", "longName": "Grifols, S.A.", "firstTradeDateEpochUtc": 1214314200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "bfb74bd0-d183-3e44-aa21-433efa561cd3", "gmtOffSetMilliseconds": -14400000, "currentPrice": 8.65, "recommendationKey": "none", "totalCash": 2259549952, "totalCashPerShare": 3.325, "ebitda": 1111435008, "totalDebt": 11504876544, "quickRatio": 0.777, "currentRatio": 1.682, "totalRevenue": 6810643968, "debtToEquity": 138.692, "revenuePerShare": 9.403, "returnOnAssets": 0.02473, "returnOnEquity": 0.028169999, "freeCashflow": 159467632, "operatingCashflow": 376582016, "earningsGrowth": -0.667, "revenueGrowth": 0.093, "grossMargins": 0.38764, "ebitdaMargins": 0.16319, "operatingMargins": 0.16194001, "financialCurrency": "EUR", "trailingPegRatio": 0.2195, "__fetch_time": "2024-09-05"}]